Business Context and Reporting Period
Company: Biogen Idec Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Overview: Biogen Idec is a global biotechnology company focused on oncology, neurology, and immunology. The company's revenue is heavily concentrated in two principal products: AVONEX (multiple sclerosis) and RITUXAN (oncology and rheumatoid arthritis), which together represented approximately 94% of total revenues in 2006. The year was marked by the reintroduction of TYSABRI (multiple sclerosis) in the U.S. and Europe following a 2005 suspension, the acquisition of Fumapharm AG (adding FUMADERM and BG-12), and the divestiture of the AMEVIVE product line.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Total Revenues | $2,683.0 million | $2,422.5 million |
| Net Income | $217.5 million | $160.7 million |
| Diluted EPS | $0.63 | $0.47 |
| Operating Cash Flow | $841.3 million | $889.5 million |
| Cash, Equivalents & Marketable Securities | $2,314.9 million | $2,055.1 million |
| Total Assets | $8,552.8 million | $8,381.7 million |
| Long-Term Debt (Notes Payable) | $96.7 million | $43.4 million |
Revenue Breakdown (2006):
- Product Revenues: $1,781.3 million (66.5%)
- Unconsolidated Joint Business (RITUXAN): $810.9 million (30.2%)
- Other Revenues (Royalties): $90.9 million (3.3%)
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 10.8% to $2.68 billion, driven by growth in AVONEX sales ($1.71 billion, +10.6%) and RITUXAN joint business profits ($555.8 million share, +8.2%).
- Acquisitions & Charges: The company recorded a significant non-cash charge of $330.5 million for acquired in-process research and development (IPR&D) related to the acquisitions of Fumapharm ($207.4 million) and Conforma ($123.1 million).
- Product Portfolio Changes:
- TYSABRI: Reintroduced in Q3 2006, generating $35.8 million in revenue compared to $4.7 million in 2005.
- AMEVIVE: Sold to Astellas in April 2006; revenue dropped to $11.5 million from $48.5 million in 2005.
- ZEVALIN: Divestiture plan initiated in Q3 2006; revenue declined to $17.8 million from $20.8 million.
- Profitability: Net income increased 35.4% despite the IPR&D charges, aided by a $15.6 million gain on the sale of a research facility and lower facility impairment charges compared to 2005.
Guidance, Outlook, and Risks
Outlook: Management expects continued growth dependent on the successful commercialization of TYSABRI and the expansion of RITUXAN indications (specifically in rheumatoid arthritis and maintenance therapy for lymphoma). Long-term growth relies on the pipeline, including BG-12 (Phase III for MS) and galiximab (Phase III for NHL).
Key Risks & Contingencies:
- Product Liability & Safety: TYSABRI carries a risk of Progressive Multifocal Leukoencephalopathy (PML). The product is marketed under a strict risk management program (TOUCH). Two deaths from PML were reported in patients treated for SLE (an unapproved indication).
- Legal Proceedings:
- Securities Litigation: Class action lawsuits allege false statements regarding TYSABRI safety prior to its 2005 suspension.
- Government Investigations: Ongoing SEC investigation regarding TYSABRI suspension; DOJ investigation into RITUXAN promotion practices (involving partner Genentech).
- Medicaid Litigation: Multi-district litigation alleging fraudulent reporting of Average Wholesale Prices for Medicaid reimbursement.
- Collaboration Disputes: Arbitration filed against Genentech regarding strategic decision-making rights and a disputed "change of control" claim related to the 2003 merger.
- Manufacturing: Significant capital investment ($225 million additional commitment) in a new manufacturing facility in Hillerod, Denmark, creates exposure if demand forecasts are not met.
Investor Verification Checklist
- TYSABRI Market Acceptance: Verify the rate of physician adoption and patient enrollment in the TOUCH risk management program post-reintroduction.
- RITUXAN Profit Sharing: Confirm the impact of new anti-CD20 product approvals on the profit-sharing formula with Genentech, which could reduce Biogen Idec's share of RITUXAN profits.
- Legal Exposure: Monitor the status of the securities class action and the DOJ investigation into RITUXAN promotion, as outcomes could result in significant fines or settlements.
- Pipeline Progress: Track clinical trial results for BG-12 (MS) and the potential for new RITUXAN indications (Lupus, MS) to ensure future revenue diversification beyond AVONEX and RITUXAN.
- Manufacturing Capacity: Assess the timeline and cost overruns for the Hillerod, Denmark facility expansion, which is critical for TYSABRI supply.